Skip to content

Prime Medicine PRME Free cash flow

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.29B+66.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$117.43M+21.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$109.4M-102%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$130.75M-22.2%
Regenxbio logo
RegenxbioRGNX
-$77.42M-337%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Calculated from Prime Medicine’s reported figures.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's free cash flow?
Prime Medicine (PRME) reported free cash flow of -$42.92M in Q1 2026.
How has Prime Medicine's free cash flow changed year-over-year?
Prime Medicine's free cash flow increased by 16.3% year-over-year, from -$51.28M to -$42.92M.
What is the long-term trend for Prime Medicine's free cash flow?
Over 2 years (2022 to 2025), Prime Medicine's free cash flow has grown at a 6.3% compound annual growth rate (CAGR), from -$147.92M to -$167.1M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.